US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease
24 Julio 2024 - 1:00PM
Autoimmune hemolytic anemia (AIHA) encompasses a group of rare
disorders characterized by the destruction of red blood cells due
to autoantibodies. Among these, warm autoimmune hemolytic anemia
(w-AIHA) stands out as the most common form, representing 70-80% of
all AIHA cases, with cold agglutinin disease (CAD), making up most
of the remaining cases.1 While there is one approved agent to treat
CAD – Enjaymo by Sanofi, there are no approved products yet to
treat w-AIHA, leading to a high unmet need for effective treatment
options across both conditions.
Spherix Global Insights’ latest Market Dynamix™ (US)
research on AIHA – diving into w-AIHA and CAD specifically –
highlights challenges in the treatment landscape from the
perspective of hematologists (n=58). The studies reveal that the
majority of respondents identify a high unmet need in AIHA
treatments overall, with nearly two-thirds emphasizing the need for
new therapies specifically for w-AIHA. This represents the highest
unmet need among all AIHA conditions, with CAD also among the top
three.
The most frequently expressed concerns among hematologists
include the lack of effective treatment options and the challenges
associated with long-term steroid use. Steroids, while a common
treatment, come with significant drawbacks that often lead to the
need for second-line therapies such as rituximab. Consequently,
there is a clear and pressing demand for new treatments that offer
better efficacy and a more favorable safety profile.
In addition to these treatment challenges, hematologists also
emphasize the need for high-quality evidence to support AIHA
treatment guidelines. Nearly all respondents agree on the
importance of generating robust clinical data to guide treatment
decisions and improve patient care. Furthermore, the study
highlights that the most desired attributes for new AIHA therapies
include the ability to avoid long-term steroid use and the absence
of severe adverse effects.
Overall, the AIHA treatment pipeline has many opportunities,
with numerous upcoming therapies – especially in w-AIHA – expected
to bring meaningful advancements to the management of these
challenging conditions. Assets under development and included in
the study include Johnson & Johnson’s nipocalimab, Novartis’
ianalumab, Zenas BioPharma’s obexelimab, and Sanofi’s
rilzabrutinib, among others. This excitement for emerging therapies
highlights a dynamic and promising future for the AIHA treatment
landscape, brimming with potential for breakthroughs and
innovations in the near future.
The full findings from Spherix Global Insights’ Market
Dynamix™: AIHA (US) 2024 study was released earlier this week
to subscribed clients, offering an in-depth analysis of these
trends and providing valuable insights into the future of AIHA
treatment.
Market Dynamix™ is an independent service providing
analysis of markets anticipated to experience a paradigm shift
within the next three to five years. Insights highlight market
size, current treatment approaches, unmet needs, and expert
opinions on the likely disruption introduced by pipeline
agents.
1Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematology
Am Soc Hematol Educ Program. 2016;1:690-697.
About Spherix Global Insights
Spherix is a leading independent market intelligence and
advisory firm that delivers commercial value to the global life
sciences industry, across the brand lifecycle.
The seasoned team of Spherix experts provides an unbiased and
holistic view of the landscape within rapidly evolving specialty
markets, including dermatology, gastroenterology, rheumatology,
nephrology, neurology, and ophthalmology. Spherix clients stay
ahead of the curve with the perspective of the extensive Spherix
Physician Community.
As a trusted advisor and industry thought leader, Spherix’s
unparalleled market insights and advisory services empower clients
to make better decisions and unlock opportunities for growth.
To learn more about Spherix Global Insights,
visit spherixglobalinsights.com or connect
through LinkedIn.
For more details on Spherix’s primary market research reports
and interactive dashboard offerings, visit or register
here: https://clientportal.spherixglobalinsights.com
Spherix Global Insights Contacts
Tucker Hurtado, Hematology Launch Franchise
Headtucker.hurtado@spherixglobalinsights.com
NOTICE: All company, brand or product names in this press
release are trademarks of their respective holders. The findings
and opinions expressed within are based on Spherix Global Insight’s
analysis and do not imply a relationship with or endorse.
Tucker Hurtado, Hematology Launch Franchise Head
Spherix Global Insights
4848794284
tucker.hurtado@spherixglobalinsights.com